Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator

Abstract

Methods and compositions for inhibiting the hepatic clearance of tissue-type plasminogen activator (t-PA) in vivo by administering a t-PA-hepatic clearance-inhibiting amount of 39 kDa protein or a t-PA-hepatic clearance-inhibiting fragment thereof, or genetically or chemically modified forms of the 39 kDa protein or fragments thereof are described. Methods and compositions for treatment of thrombolytic diseases by administering t-PA and a t-PA-hepatic clearance-inhibiting effective amount of 39 kDa protein, a t-PA-hepatic clearance inhibiting fragment thereof, and genetically or chemically modified forms of the 39 kDa protein or its fragments are described.

Dependencies are inferred from the claim text.